
Federica Predolini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/494111/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12238-12243.	7.1	181
2	Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. Gynecologic Oncology, 2015, 138, 11-17.	1.4	68
3	SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. Molecular Cancer Therapeutics, 2016, 15, 1900-1909.	4.1	55
4	Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecologic Oncology, 2017, 144, 146-152.	1.4	55
5	SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. Clinical Cancer Research, 2017, 23, 5836-5845.	7.0	51
6	Dual-Targeting Nanoparticles for <i>In Vivo</i> Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells. Molecular Cancer Therapeutics, 2017, 16, 323-333.	4.1	34
7	Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i> . Molecular Cancer Therapeutics, 2015, 14, 2519-2526.	4.1	30
8	Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. Journal of Experimental and Clinical Cancer Research, 2015, 34, 123.	8.6	29
9	Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. Gynecologic Oncology, 2015, 139, 112-117.	1.4	27
10	Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. British Journal of Cancer, 2016, 115, 303-311.	6.4	27
11	Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines inÂvitro. American Journal of Obstetrics and Gynecology, 2016, 214, 99,e1-99,e8.	1.3	17